Clinical Trials Using JAK1 Inhibitor INCB039110

Clinical trials are research studies that involve people. The clinical trials on this list are studying JAK1 Inhibitor INCB039110. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

    The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
    Location: 17 locations

  • Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

    This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib to participants from Incyte-sponsored studies of parsaclisib.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • Itacitinib and Alemtuzumab in Treating Patients with T-Cell Prolymphocytic Leukemia

    This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Itacitinib in Reducing the Incidence of Graft Versus Host Disease in Patients with Hematologic Cancers Undergoing Donor Stem Cell Transplant

    This phase I trial studies the side effects of itacitinib in reducing the incidence of graft versus host disease (GVHD) in patients with hematologic (bone marrow and blood cells) cancers undergoing donor stem cell transplant. One of the side effects of a donor stem cell transplant is the development of GVHD, which occurs when some of the cells from the donor attack the recipient’s tissues, resulting in mild, moderate, or even life-threatening side effects to the recipient’s skin, stomach, intestine, and liver. Itacitinib may prevent or lessen the effect of GVHD while still effectively treating the hematologic cancer.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Itacitinib and Everolimus in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma

    This phase I / II trial studies the side effects and best dose of itacitinib when given together with everolimus in treating patients with classic Hodgkin lymphoma that has come back or does not respond to treatment. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving itacitinib with everolimus may work better in treating patients with classic Hodgkin lymphoma compared to giving itacitinib or everolimus alone.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Itacitinib in Treating Patients with Refractory Metastatic / Advanced Soft Soft Tissue Sarcomas

    This pilot phase I trial studies how well itacitinib works in treating patients with soft tissue sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced / metastatic). Itacitinib may cause changes in the immune system and the body's immune response to cancer, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Pembrolizumab and Itacitinib in Treating Patients with Previously Untreated PD-L1 Positive Stage IV Non-Small Cell Lung Cancer

    This phase II trial studies the side effects of itacitinib when given with itacitinib, and to see how well they work in treating patients with stage IV non-small cell lung cancer expressing PD-L1. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab with itacitinib may work better in treating patients with stage IV non-small cell lung cancer expressing PD-L1.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome after Donor Hematopoietic Cell Transplant

    This phase I trial studies how well itacitinib works for the treatment of bronchiolitis obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

    The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive tisagenlecleucel or axicabtagene ciloleucel immune effector cell (IEC) therapy for any approved hematologic indication.
    Location: 8 locations

  • GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

    The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
    Location: 5 locations